Skip to content

Efficacy of Amoxicillin-metronidazole Compared to Clindamycin in Patients With Periodontitis and Diabetes

Efficacy of Amoxicillin-metronidazole Compared to Clindamycin in the Treatment of Periodontitis in Patients With Diabetes

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03374176
Enrollment
42
Registered
2017-12-15
Start date
2014-03-31
Completion date
2017-09-30
Last updated
2020-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Periodontal Pocket, Periodontitis

Keywords

periodontitis, diabetes mellitus, systemic antimicrobials

Brief summary

Periodontitis is an inflammation of the supporting structures of the teeth, usually caused by specific or groups of microorganisms that results in the progressive destruction of the periodontal ligament and alveolar bone. the objective of periodontitis treatment is to reduce the number of periodontal pathogens. However, there is not an agreement in the use of systemic antibiotics in patients with diabetes. The purpose of the present study was to determine the efficacy of amoxicillin/metronidazole compared to clindamycin during non-surgical treatment of periodontitis in patients with type 2 diabetes mellitus. Patients and methods In this double-blind, randomized clinical trial, a total of 42 patients with chronic periodontitis and type 2 diabetes were included in a 24-months follow-up. Patients were randomly assigned to treatment with either amoxicillin/metronidazole or clindamycin every for 7 days. Clinical determinations (depth of probing, bleeding at the probe and plaque index) were performed to determine the extent and severity of periodontitis before and after the pharmacological treatment. The intra-group differences were calculated with Wilcoxon rank test. The inter-group differences were calculated with Mann-Whitney test. Sex, bacterial plaque, and bleed to the sounding were summarized using proportions and analyzed with the chi-square method. In all analyses, a P-value of \<0.05 (two tailed) was considered statistically significant

Detailed description

A parallel, randomized, double-blind, active controlled, single center clinical trial was designed to compare the efficacy of two antibiotic therapies with 24-month follow-up. The study protocol was approved by the ethical committee of the Universitary Center of Health Sciences of University of Guadalajara and conducted according to Good Clinical Practice and the principles of the Declaration of Helsinki. All patients provided written informed consent before the initiation of study procedures. A total of 5 non-study subjects with chronic periodontitis were recruited and used for the calibration exercise. Two designated examiners measured full-mouth probing pockets depths (PPD) for all 5 subjects. On the same day (with a minimum of 15 min separation), the examiner repeated the examination. Upon completion of all measurements, the intra-examiner repeatability for PPD measurement was assessed. The examiner was judged to be reproducible after fulfilling the pre-determined success criteria (the percentage of agreement within 2 mm between repeated measurements had to be at least 70 %). The examiner showed 78.3 % reproducibility. The sample size was calculated with a 95% confidence level and statistical power of 80 %. A standard deviation of 1.0 mm with an expected difference of 1.0 mm probing pocket depth reduction between treatments. This resulted in a total of 14 patients per arm, however this sample was increased 20% (21 patients per group) to compensate for possible dropouts. Patient population Criteria for selection Patients of both sexes (aged \>18 to 70 years) with a diagnosis of chronic periodontitis according to the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions and a history of type 2 diabetes with a HbA1C \< 8 % and a fasting plasma glucose (FPG) \< 180 mg/dL. Patients with aggressive periodontitis, pregnant or lactating females, required antibiotic pre-medication for the performance of periodontal examination and treatment or received antibiotic treatment in the previous 3 months were excluded. A history of anti-inflammatory therapy within preceding six months or that had received a course of periodontal treatment within the last 6 months, allergies to penicillin, metronidazole or clindamycin, and were not able to provide consent to participate in the study were also criteria for exclusion. Intervention Subjects were randomly allocated 1:1 to receive 500 mg amoxicillin + 250 mg metronidazole or 300 mg clindamycin + placebo using a computer that generated a list of random numbers. Subjects were instructed to take the treatment three times a day for 7 days in both groups. Assessments During these sessions, a case presentation was given to each subject related to the specific features of his/her disease, as well as a supra- and sub-gingival mechanical debridement was performed. A complete periodontal examination was performed, including a full medical and dental history, an intra-oral examination and a full-mouth periodontal probing. A radiographic examination was undertaken using either periapical x-rays or a ortopantomography. Clinical parameters Clinical parameters were assessed using a North Caroline Periodontal Probe by the calibrated examiner at six sites. Full-mouth plaque scores were recorded by assigning a binary score to each surface (1 for plaque present, 0 for absent) and by calculating the percentage of total tooth surfaces that revealed the presence of plaque detected by the use of tablet. Similarly, a full-mouth percentage bleeding score was calculated after assessing dichotomously the presence of bleeding on probing from the bottom of the pocket when probing with a manual probe with a force of 0.3n. Full-mouth PPD and recession of the gingival margin were recorded at the same time with measurements rounded to the nearest millimeter. Non-surgical periodontal therapy Periodontal therapy was initiated within 1 month of the baseline screening examination. A standard cycle of periodontal therapy consisting of oral hygiene instructions, supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planning) was performed by two experienced therapists. Local anesthesia was used as necessary. Patients relied on standard oral hygiene methods as instructed at the commencement of the study. Post-treatment controls The objectives of the post-treatment appointments were to control and reinforce the oral hygiene habits of each subject, to monitor the early healing events and to report any adverse events or additional medications taken. In addition, the 1-week post-treatment visit served as a compliance control, as subjects were asked to return any medication not taken and/or the empty bottles. The number of pills not taken by the study subjects was documented. Re-assessment examinations Reassessment visits occurred within a month and a half of the completion of the pharmacological treatment. During these appointments, the examiner recorded any changes in the medical history and repeated clinical periodontal parameters recorded at the basal visit. Statistical analysis Age, FPG, HbA1C, tooth, and sounding depth were presented in means and standard deviation. The intra-group differences were calculated with Wilcoxon rank test. The inter-group differences were calculated with Mann-Whitney test. Sex, bacterial plaque, and bleed to the sounding were summarized using proportions and analyzed with the chi-square method. In all analyses, a P-value of \<0.05 (two tailed) was considered statistically significant. All statistical analyses were conducted using SPSS software (IBM Corporation, Armonk, NY, USA) version 21.

Interventions

DRUGAmoxicillin 500 mg / Metronidazole 250 mg

Subjects were instructed to take a capsule three times a day for 7 days

Subjects were instructed to take a capsule three times a day for 7 days

Sponsors

Centro Universitario de Tonalá
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients of both sexes * Age \>18 to 70 years * Diagnosis of chronic periodontitis according to the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions * History of type 2 diabetes * HbA1C \< 8 % * Fasting plasma glucose (FPG) \< 180 mg/dL.

Exclusion criteria

* Aggressive periodontitis * Pregnant or lactating females, * Required antibiotic pre-medication for the performance of periodontal examination and treatment or received antibiotic treatment in the previous 3 months were excluded. * A history of anti-inflammatory therapy within preceding six months * Had received a course of periodontal treatment within the last 6 months, * Allergies to penicillin, metronidazole or clindamycin, * Not able to provide consent to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Probing Depth7 daysThe size of the periodontal pocket

Secondary

MeasureTime frameDescription
Sites With Plaques7 days0: no plaque 1. separate flecks of plaque at the cervical margin of the tooth 2. a thin continuous band of plaque (up to 1 mm) at the cervical margin of the tooth 3. a continuous band of plaque wider than 1 mm but covering less than one-third of the crown of the tooth 4. plaque covering at least one-third but less than two-thirds of the crown of the tooth 5. plaque covering two-thirds or more of the crown of the tooth. A higher scores mean a worse outcome
Sites With Bleeding on Probing7 daysRefers to bleeding on probing 0: absence of inflammation 1. mild inflammation; a slight change in color, little change in the texture of any portion of but not the entire marginal or papillary gingival unit 2. mild inflammation; criteria as above but involving the entire marginal or papillary gingival unit 3. moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit 4; severe inflammation; marked redness, edema, and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration
Total Count of All Teeth Lost Across All Participants2 yearsThe total count of all teeth lost in all participants.

Participant flow

Recruitment details

The study was carried out on patients at the Integral Dentistry Clinics of the University Center of Health Sciences of the University of Guadalajara in Jalisco, Mexico. The participants attended for dental care from August 2015 to December 2016.

Pre-assignment details

A radiographic examination was undertaken using either periapical films or a pantomogram. Periodontal therapy was initiated within 1month of the baseline screening examination.

Participants by arm

ArmCount
AMX-MET
500 mg amoxicillin plus 250 mg metronidazole three times a day for 7days
21
Clindamycin
300mg clindamycin plus placebo three times a day for 7days
21
Total42

Baseline characteristics

CharacteristicAMX-METClindamycinTotal
Age, Continuous52.5 years
STANDARD_DEVIATION 8
52.0 years
STANDARD_DEVIATION 10.6
52.2 years
STANDARD_DEVIATION 9.3
Bleeding on Probing42.4 Sites
STANDARD_DEVIATION 24.2
55.6 Sites
STANDARD_DEVIATION 25.8
49.0 Sites
STANDARD_DEVIATION 25.6
Fasting Plasma Glucose134.1 mg/dL
STANDARD_DEVIATION 23.3
136.3 mg/dL
STANDARD_DEVIATION 25.7
135.2 mg/dL
STANDARD_DEVIATION 24.2
HbA1C7.1 %
STANDARD_DEVIATION 0.4
7.3 %
STANDARD_DEVIATION 0.4
7.2 %
STANDARD_DEVIATION 0.4
Number of Teeth present in the subjects25 Teeth
STANDARD_DEVIATION 3
24 Teeth
STANDARD_DEVIATION 5
24 Teeth
STANDARD_DEVIATION 4
Probing depth2.4 mm
STANDARD_DEVIATION 0.6
2.6 mm
STANDARD_DEVIATION 0.6
2.5 mm
STANDARD_DEVIATION 0.6
Sex: Female, Male
Female
10 Participants14 Participants24 Participants
Sex: Female, Male
Male
11 Participants7 Participants18 Participants
Sites with Plaque40.4 Sites
STANDARD_DEVIATION 22.9
40.7 Sites
STANDARD_DEVIATION 21.9
40.5 Sites
STANDARD_DEVIATION 22.1

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 210 / 21
other
Total, other adverse events
0 / 210 / 21
serious
Total, serious adverse events
0 / 210 / 21

Outcome results

Primary

Probing Depth

The size of the periodontal pocket

Time frame: 7 days

ArmMeasureValue (MEAN)Dispersion
AMX-METProbing Depth0.44 mmStandard Deviation 0.27
ClindamycinProbing Depth0.50 mmStandard Deviation 0.17
p-value: <0.05Wilcoxon (Mann-Whitney)
Secondary

Sites With Bleeding on Probing

Refers to bleeding on probing 0: absence of inflammation 1. mild inflammation; a slight change in color, little change in the texture of any portion of but not the entire marginal or papillary gingival unit 2. mild inflammation; criteria as above but involving the entire marginal or papillary gingival unit 3. moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit 4; severe inflammation; marked redness, edema, and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration

Time frame: 7 days

ArmMeasureValue (MEAN)Dispersion
AMX-METSites With Bleeding on Probing16.1 SitesStandard Deviation 11.2
ClindamycinSites With Bleeding on Probing22.1 SitesStandard Deviation 12.9
Secondary

Sites With Plaques

0: no plaque 1. separate flecks of plaque at the cervical margin of the tooth 2. a thin continuous band of plaque (up to 1 mm) at the cervical margin of the tooth 3. a continuous band of plaque wider than 1 mm but covering less than one-third of the crown of the tooth 4. plaque covering at least one-third but less than two-thirds of the crown of the tooth 5. plaque covering two-thirds or more of the crown of the tooth. A higher scores mean a worse outcome

Time frame: 7 days

ArmMeasureValue (MEAN)Dispersion
AMX-METSites With Plaques17.6 SitesStandard Deviation 13.3
ClindamycinSites With Plaques15.8 SitesStandard Deviation 10
Secondary

Total Count of All Teeth Lost Across All Participants

The total count of all teeth lost in all participants.

Time frame: 2 years

ArmMeasureValue (NUMBER)
AMX-METTotal Count of All Teeth Lost Across All Participants0 total count of all teeth lost
ClindamycinTotal Count of All Teeth Lost Across All Participants0 total count of all teeth lost

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026